SMH
·general
·1 hour ago
NeuroScientific hails 80% clinical response in Crohn’s stem cell program
NeuroScientific Biopharmaceuticals reported an 80% clinical response rate in its StemSmart stem cell therapy for fistulising Crohn's disease, with four of five patients demonstrating meaningful improvement under its Special Access Program. All patients showed symptom improvement with no serious adverse events, and all had surgical drains removed, indicating healing.
Summary by Glance · SMH
Newer
Next
Loving doing this? 🎉
Take it further — get the full app and never miss a moment of what's happening in Australia.
Breaking news alerts
Instant lock-screen notifications the moment big stories break across Australia.
Australian news & events
Politics, sport, weather, local events — all in one swipeable feed, updated around the clock.
Stay ahead of the news cycle
30-second summaries so you're always informed, even on your busiest days.
Loading article…
This publisher's site can't be shown here due to their security settings.
Open full article →No source link available for this article.
✨
Ask AI